An improved LC–MS/MS method for simultaneous evaluation of CYP2C9, CYP2C19, CYP2D6 and CYP3A4 activity

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ‘cocktail’ approach. Clin. Pharmacol. Ther. 81(2), 270–283 (2007). • Discusses the basics and requirements of cytochrome P450 (CYP) phenotyping and different substrates for each of the CYP isoenzymes. It also discusses the advantages and problems of the cocktail approach and a summary of all CYP phenotyping cocktails that have been published until 2007.
  Medline CASGoogle Scholar
• 2 Christensen M, Andersson K, Dalen P et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin. Pharmacol. Ther. 73(6), 517–528 (2003).
  Medline CASGoogle Scholar
• 3 Ghassabian S, Chetty M, Tattam BN et al. A high-throughput assay using liquid chromatography–tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients. Ther. Drug Monit. 31(2), 239–246 (2009).
  Medline CASGoogle Scholar
• 4 de Andres F, Sosa-Macias M, Llerena A. A rapid and simple LC–MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity. Bioanalysis 6(5), 683–696 (2014).
  CASGoogle Scholar
• 5 Bosilkovska M, Samer CF, Deglon J et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin. Pharmacol. Ther. 96(3), 349–359 (2014).
  Medline CASGoogle Scholar
• 6 Ryu JY, Song IS, Sumwoo YE et al. Development of the ‘Inje cocktail’ for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther. 82(5), 531–540 (2007). •• Used the five substrates for the major CYP isoenzymes for the first time and they showed that there is no interaction among those substrates, and the substrates possessed produce low adverse effects and are specific for each of the CYP enzymes of interest.
  Medline CASGoogle Scholar
• 7 Tanaka S, Uchida S, Inui N et al. Simultaneous LC–MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites. Biol. Pharm. Bull. 37(1), 18–25 (2014).
  Medline CASGoogle Scholar
• 8 Oh KS, Park SJ, Shinde DD et al. High-sensitivity liquid chromatography–tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 895–896, 56–64 (2012).
  Medline CASGoogle Scholar
• 9 Puris E, Pasanen M, Gynther M et al. A liquid chromatography–tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urine. Anal. Bioanal. Chem. 409(1), 251–268 (2017).
  Medline CASGoogle Scholar
• 10 Tanaka E, Kurata N, Yasuhara H. How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J. Clin. Pharm. Ther. 28(3), 157–6165 (2003).
  Medline CASGoogle Scholar
• 11 de Andres F, Teran S, Bovera M et al. Multiplex phenotyping for systems medicine: a one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach. Integr. Biol. 20(2), 88–96 (2016). • Promoted the use of a one-point sampling strategy for CYP phenotyping that will be ideal.
  CASGoogle Scholar
• 12 Donzelli M, Derungs A, Serratore MG et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet. 53(3), 271–282 (2014).
  Medline CASGoogle Scholar
• 13 EMA. Guidance on Bioanalytical Method Validation (2011). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
  Google Scholar
• 14 Petsalo A, Turpeinen M, Pelkonen O et al. Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography–tandem mass spectrometry utilizing sub 2 microm particle size column. J. Chromatogr. A 1215(1-2), 107–115 (2008).
  Medline CASGoogle Scholar
• 15 Chen R, Zheng X, Hu P. CYP2D6 phenotyping uisng urine, plasma, and saliva metabolic ratios to assess the impact of CYP2D6*10 on interindividual variation in a chineses population. Front Pharmacol. 8, 239 (2017). •• The authors found a significant correlation between urinary magnetic resonance and plasma magnetic resonance (Spearman r = 0.78). This finding makes using plasma instead of the more cumbersome urine samples justified.
  MedlineGoogle Scholar
• 16 Hennion MC. Solid-phase extraction: method development, sorbents, and coupling with liquid chromatography. J. Chromatogr. A. 856(1–2), 3–54 (1999).
  Medline CASGoogle Scholar
• 17 Wang S, Cyronak M, Yang E. Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma. J. Pharm. Biomed. Anal. 43(2), 701–707 (2007).
  Medline CASGoogle Scholar
• 18 Kumar A, Mann HJ, Remmel RP. Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 853(1–2), 287–293 (2007).
  Medline CASGoogle Scholar
• 19 Yin OQ, Lam SS, Lo CM et al. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid. Commun. Mass. Spectrom. 18(23), 2921–2933 (2004).
  Medline CASGoogle Scholar
• 20 Chainuvati S, Nafziger AN, Leeder JS et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the ‘Cooperstown 5 + 1 cocktail’. Clin. Pharmacol. Ther. 74(5), 437–447 (2003). • Addresses the basics of the CYP phenotyping cocktail approach that was been used by many other researchers.
  Medline CASGoogle Scholar